Schwab K et al., 2018-01-10: Mouse and cell-culture study showing LMTM reduces alpha-synuclein inclusions and rescues motor and anxiety traits in two transgenic mouse lines. It is not a human trial.
The results suggest that LMTM may provide a potential disease modification therapy in PD and other synucleinopathies through the inhibition of α-Syn aggregation.
Schwab K et al., 2018-01-10: Mouse and cell-culture study showing LMTM reduces alpha-synuclein inclusions and rescues motor and anxiety traits in two transgenic mouse lines. It is not a human trial. Study type: cell line (N1E-115 neuroblastoma) plus two transgenic mouse lines (L58, L62); EC50 1.1 µM in cells, 5 and 15 mg MT/kg/day oral for 6 weeks in mice. Country: Germany/UK. Authors include TauRx Therapeutics staff (Wischik, Harrington, Storey, Baddeley). Comparator: vehicle-treated transgenic animals. No human Parkinson's disease or Lewy body dementia trial of methylthioninium exists: queries of ClinicalTrials.gov API v2 for 'hydromethylthionine', 'methylthioninium', 'LMTM', 'TRx0237' and 'methylene blue' returned only Alzheimer's disease, bvFTD, and non-neurological indications – no Parkinson's or DLB study. Animal-only evidence cannot support a claim about human benefit. Study type: animal.
